- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ATL's HDI 3000 takes center stage
Ultrasound vendor ATL will usethe RSNA meeting to build on the momentum generated by the Octoberlaunch of HDI 3000, the company's new premium scanner (SCAN 10/26/94).HDI 3000 represents the fourth generation of ATL's all-digitalultrasound technology,
Ultrasound vendor ATL will usethe RSNA meeting to build on the momentum generated by the Octoberlaunch of HDI 3000, the company's new premium scanner (SCAN 10/26/94).HDI 3000 represents the fourth generation of ATL's all-digitalultrasound technology, according to president David Perozek.
In designing HDI 3000, ATL, of Bothell, WA, strove to developa system with improved performance in a more compact, easy-to-usepackage, Perozek said. The scanner weighs 380 pounds and featuresspecially designed wheels as well as a new suspension system tomake it easier to move.
ATL has improved the scanner's image quality over previousmodels by developing a new generation of application-specificintegrated circuits (ASICs), as well as a new software architecture.The system is a 128-channel scanner, like ATL's Ultramark 9 HDIsystem, which will remain in the company's product line.
In addition to HDI, ATL will showcase its Access ultrasoundimage management system, which was cleared by the Food and DrugAdministration this year (SCAN 8/31/94). Access is a PC-basedsystem running on IBM's OS/2 operating system. ATL will show threeworkstations for use with Access, which is DICOM 3.0-compatiblethroughout the system, Perozek said.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
